Taking on analysts’ expectations and winning: Adma Biologics Inc (ADMA)

Adma Biologics Inc (NASDAQ: ADMA) stock jumped 1.51% on Monday to $4.03 against a previous-day closing price of $3.97. With 2.77 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.08 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.0700 whereas the lowest price it dropped to was $3.9300. The 52-week range on ADMA shows that it touched its highest point at $4.65 and its lowest point at $2.94 during that stretch. It currently has a 1-year price target of $6.00. Beta for the stock currently stands at 0.83.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ADMA was up-trending over the past week, with a rise of 7.75%, but this was up by 27.53% over a month. Three-month performance surged to 4.13% while six-month performance fell -2.89%. The stock gained 26.73% in the past year, while it has gained 3.87% so far this year. A look at the trailing 12-month EPS for ADMA yields -0.11 with Next year EPS estimates of 0.16. For the next quarter, that number is 0.01. This implies an EPS growth rate of 91.67% for this year and 690.91% for next year.

Float and Shares Shorts:

At present, 221.82 million ADMA shares are outstanding with a float of 216.53 million shares on hand for trading. On Oct 30, 2023, short shares totaled 9.58 million, which was 4.24% higher than short shares on Sep 28, 2023. In addition to Mr. Adam S. Grossman as the firm’s Co-Founder, President, CEO & Director, Dr. Jerrold B. Grossman D.P.S., Ph.D. serves as its Co-Founder & Vice Chairman of the Board.

Institutional Ownership:

Through their ownership of 77.72% of ADMA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 47.85% of ADMA, in contrast to 29.47% held by mutual funds. Shares owned by individuals account for 24.68%. As the largest shareholder in ADMA with 6.71% of the stake, BlackRock Fund Advisors holds 15,091,183 shares worth 15,091,183. A second-largest stockholder of ADMA, The Vanguard Group, Inc., holds 12,293,683 shares, controlling over 5.47% of the firm’s shares. SSgA Funds Management, Inc. is the third largest shareholder in ADMA, holding 9,601,938 shares or 4.27% stake. With a 2.85% stake in ADMA, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 6,411,673 shares are owned by the mutual fund manager. The SPDR S&P Biotech ETF, which owns about 2.41% of ADMA stock, is the second-largest Mutual Fund holder. It holds 5,420,746 shares valued at 18.32 million. iShares Russell 2000 ETF holds 2.15% of the stake in ADMA, owning 4,844,763 shares worth 16.38 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ADMA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ADMA analysts setting a high price target of $7.00 and a low target of $5.00, the average target price over the next 12 months is $6.00. Based on these targets, ADMA could surge 73.7% to reach the target high and rise by 24.07% to reach the target low. Reaching the average price target will result in a growth of 48.88% from current levels.

Summary of Insider Activity:

Insiders traded ADMA stock several times over the past three months with 2 Buys and 2 Sells. In these transactions, 155,000 shares were bought while 33,986 shares were sold. The number of buy transactions has increased to 25 while that of sell transactions has risen to 23 over the past year. The total number of shares bought during that period was 3,965,439 while 3,836,010 shares were sold.